Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the relationship between the gut microbiome and the host genome and transcriptome in colorectal cancer (CRC). Researchers profiled the fecal microbiome structure alongside genomic and transcriptomic data from matched tumor and normal mucosa tissue. Exome sequencing was used to identify somatic mutations, and gene expression patterns were annotated and clustered against microbial abundance data. Immune and stromal cell composition was also estimated from the transcriptomic profiles.
Who was studied?
The cohort consisted of 41 patients with colorectal cancer. For each patient, matched tumor tissue and normal mucosa tissue were analyzed alongside fecal microbiome samples. The abstract does not provide further demographic details such as age, sex, or geographic origin of the participants.
What were the most important findings?
The researchers identified 22 gut microbial species significantly associated with CRC and estimated relative abundance across functional (KEGG) pathway categories. Four significantly mutated genes, TP53, APC, KRAS, and SMAD4, were linked to specific cancer-associated microbes. Fusobacterium nucleatum in particular showed a positive correlation with multiple host metabolic pathways, tying a specific pathogen to altered tumor metabolism. The abstract text is truncated before further results are described.
What are the greatest implications of this study?
The findings support a functional link between specific gut bacteria, such as Fusobacterium nucleatum, and the somatic mutation landscape and metabolic activity of colorectal tumors. This multi-omic approach suggests that microbial taxa may interact with host driver mutations like TP53, APC, KRAS, and SMAD4 rather than merely coexisting with the tumor. Such associations could inform future work on microbiome-informed risk stratification or targets in CRC, though the abstract does not describe therapeutic testing or outcomes.